{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:40:36Z","timestamp":1770975636219,"version":"3.50.1"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Nephrology has benefited from a growing body of high-quality clinical evidence, including clinical trials of pharmacological therapies and health service research on alternative care approaches. Consequently, there is an increasing need to perform economic evaluations in kidney disease to inform reimbursement decisions and optimise healthcare spending, thereby improving patient care within budget constraints. Cost-effectiveness assesses if the additional health gains are worth any additional costs by estimating differences in the quality and quantity of life, and the costs, from the point of intervention over observed but also longer (even lifetime) timelines, capturing the entire patient pathway through healthcare, e.g. from early-stage chronic kidney disease (CKD) through to dialysis or transplantation. Working with stakeholders to define the decision problem, merging evidence from a range of sources, including clinical trials complicated by limited follow-up and non-generalisable participants, surrogacy studies to estimate the intervention\u2019s impact on longer-term kidney failure risk, quality of life data collected ideally using instruments sensitive to kidney disease progression and other real-world data are required to make extrapolations sufficiently far into the patient\u2019s lifetime to capture kidney failure. Consideration of disadvantaged populations and how interventions may operate differently in certain groups may be indicated. Failure to capture competing risks of cardiovascular disease and death will bias estimates of kidney failure. Application of our tips, combined with an understanding of how decision-makers use cost-effectiveness results and information about factors like rarity and disease severity maximises the likelihood of new kidney treatments and care approaches being adopted.<\/jats:p>","DOI":"10.1093\/ckj\/sfaf386","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:51:38Z","timestamp":1765284698000},"source":"Crossref","is-referenced-by-count":0,"title":["10 tips on performing economic evaluation in kidney disease"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-2223","authenticated-orcid":false,"given":"James","family":"Fotheringham","sequence":"first","affiliation":[{"name":"Faculty of Population Health, School of Medicine and Population Health, University of Sheffield , Sheffield ,","place":["UK"]},{"name":"Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust , Sheffield ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Hill","sequence":"additional","affiliation":[{"name":"Faculty of Population Health, School of Medicine and Population Health, University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olena","family":"Mandrik","sequence":"additional","affiliation":[{"name":"Faculty of Population Health, School of Medicine and Population Health, University of Sheffield , Sheffield ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Erickson","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Baylor College of Medicine , Houston, TX ,","place":["USA"]},{"name":"Baker Institute for Public Policy, Rice University , Houston, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2026021303311904200_bib1","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the Inside CKD Research Programme","volume":"40","author":"Jha","year":"2023","journal-title":"Adv Ther"},{"key":"2026021303311904200_bib2","doi-asserted-by":"crossref","first-page":"102615","DOI":"10.1016\/j.eclinm.2024.102615","article-title":"Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study","volume":"72","author":"Chadban","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2026021303311904200_bib3","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/CJN.03790322","article-title":"Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD","volume":"17","author":"McEwan","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021303311904200_bib4","doi-asserted-by":"publisher","first-page":"08968608251314976","DOI":"10.1177\/08968608251314976","article-title":"The clinical implications and cost-effectiveness of the provision of medical in addition to surgical catheter insertion for peritoneal dialysis in people with kidney failure","volume":"0","author":"Hill","year":"2025","journal-title":"Perit Dial Int"},{"key":"2026021303311904200_bib5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1080\/13696998.2023.2263263","article-title":"Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease","volume":"26","author":"Mata Lorenzo","year":"2023","journal-title":"J Med Econ"},{"key":"2026021303311904200_bib6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.kint.2024.12.018","article-title":"A health economic evaluation of the multinational, randomized controlled CONVINCE trial: cost-utility of high-dose online hemodiafiltration compared to high-flux hemodialysis","volume":"107","author":"Schouten","year":"2025","journal-title":"Kidney Int"},{"key":"2026021303311904200_bib7","author":"Zhang","year":"2020","journal-title":"International cost-effectiveness thresholds and modifiers for HTA decision making"},{"key":"2026021303311904200_bib8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40273-023-01348-6","article-title":"Making decision models fit for purpose: the importance of ensuring stakeholder involvement","volume":"42","author":"Harvard","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"2026021303311904200_bib9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"2026021303311904200_bib10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12882-021-02552-2","article-title":"Employment of patients with kidney failure treated with dialysis or kidney transplantation\u2014a systematic review and meta-analysis","volume":"22","author":"Kirkeskov","year":"2021","journal-title":"BMC Nephrol"},{"key":"2026021303311904200_bib11","doi-asserted-by":"publisher","first-page":"100900","DOI":"10.1016\/j.xkme.2024.100900","article-title":"Chronic kidney disease-associated pruritus burden: a patient survey study","volume":"6","author":"Thompson","year":"2024","journal-title":"Kidney Med"},{"key":"2026021303311904200_bib12","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jval.2012.06.016","article-title":"Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20142","volume":"15","author":"Roberts","year":"2012","journal-title":"Value Health"},{"key":"2026021303311904200_bib13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2022.01.010","article-title":"The history and future of the \u201cISPOR Value Flower\u201d: addressing limitations of conventional cost-effectiveness analysis","volume":"25","author":"Neumann","year":"2022","journal-title":"Value Health"},{"key":"2026021303311904200_bib14","doi-asserted-by":"publisher","first-page":"e1003954","DOI":"10.1371\/journal.pmed.1003954","article-title":"Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis","volume":"19","author":"Fletcher","year":"2022","journal-title":"PLoS Med"},{"key":"2026021303311904200_bib15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026021303311904200_bib16","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s40273-019-00835-z","article-title":"Economic modelling of chronic kidney disease: a systematic literature review to inform conceptual model design","volume":"37","author":"Sugrue","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"2026021303311904200_bib17","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/dom.14401","article-title":"Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: insights from the DISCOVER study","volume":"23","author":"Khunti","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026021303311904200_bib18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021303311904200_bib19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3899\/jrheum.161554","article-title":"Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis","volume":"45","author":"Davidson","year":"2018","journal-title":"J Rheumatol"},{"key":"2026021303311904200_bib20","doi-asserted-by":"publisher","first-page":"sfae405","DOI":"10.1093\/ckj\/sfae405","article-title":"The ERA Registry Annual Report 2022: epidemiology of kidney replacement therapy in Europe, with a focus on sex comparisons","volume":"18","author":"Boenink","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026021303311904200_bib21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12955-020-01559-x","article-title":"Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review","volume":"18","author":"Cooper","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2026021303311904200_bib22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ekir.2023.01.037","article-title":"Health care resource utilization and related costs of patients with CKD from the United States: a report from the DISCOVER CKD retrospective cohort","volume":"8","author":"Garcia Sanchez","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026021303311904200_bib23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making","volume":"26","author":"Berger","year":"2017","journal-title":"Pharmacoepidemiol Drug"},{"key":"2026021303311904200_bib24","doi-asserted-by":"publisher","first-page":"e0165675","DOI":"10.1371\/journal.pone.0165675","article-title":"Health-related quality of life impacts mortality but not progression to end-stage renal disease in pre-dialysis chronic kidney disease: a prospective observational study","volume":"11","author":"Jesky","year":"2016","journal-title":"PLoS One"},{"key":"2026021303311904200_bib25","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"2026021303311904200_bib26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/j.ajkd.2016.11.029","article-title":"Developing a set of core outcomes for trials in hemodialysis: an international Delphi survey","volume":"70","author":"Evangelidis","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2026021303311904200_bib27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.kint.2019.03.015","article-title":"An international Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis","volume":"96","author":"Manera","year":"2019","journal-title":"Kidney Int"},{"key":"2026021303311904200_bib28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12882-021-02440-9","article-title":"Development of a preliminary conceptual model of the patient experience of chronic kidney disease: a targeted literature review and analysis","volume":"22","author":"Flythe","year":"2021","journal-title":"BMC Nephrol"},{"key":"2026021303311904200_bib29","doi-asserted-by":"publisher","first-page":"e1001307","DOI":"10.1371\/journal.pmed.1001307","article-title":"A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments","volume":"9","author":"Wyld","year":"2012","journal-title":"PLoS Med"},{"key":"2026021303311904200_bib30","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.3390\/jcm11164671","article-title":"Comorbid depression and diabetes are associated with impaired health-related quality of life in chronic kidney disease patients","volume":"11","author":"Wirkner","year":"2022","journal-title":"J Clin Med"},{"key":"2026021303311904200_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/med\/9780198725923.001.0001","article-title":"7. Methods for obtaining health state utility values: generic preference-based measures of health","volume-title":"Measuring and Valuing Health Benefits for Economic Evaluation","author":"Brazier","year":"2016"},{"key":"2026021303311904200_bib32","doi-asserted-by":"publisher","first-page":"adv11604","DOI":"10.2340\/actadv.v103.11604","article-title":"Relationship between standardized measures of chronic kidney disease-associated pruritus intensity and health-related quality of life measured with the EQ-5D questionnaire: a mapping study","volume":"103","author":"Hernandez Alava","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2026021303311904200_bib33","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s10198-019-01088-5","article-title":"Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis","volume":"20","author":"Yang","year":"2019","journal-title":"Eur J Health Econ"},{"key":"2026021303311904200_bib34","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","article-title":"Estimating health-state utility for economic models in clinical studies: an ISPOR Good Research Practices Task Force report","volume":"19","author":"Wolowacz","year":"2016","journal-title":"Value Health"},{"key":"2026021303311904200_bib35","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s11136-022-03101-6","article-title":"Capturing what matters: updating NICE methods guidance on measuring and valuing health","volume":"31","author":"Dawoud","year":"2022","journal-title":"Qual Life Res"},{"key":"2026021303311904200_bib36","author":"Kidney Research UK","year":"2023","journal-title":"Kidney disease: a UK public health emergency. The health economics of kidney disease to 2023"},{"key":"2026021303311904200_bib37","doi-asserted-by":"publisher","first-page":"11786329221109755","DOI":"10.1177\/11786329221109755","article-title":"Understanding differences in health care spending: a comparative study of prices and volumes across OECD countries","volume":"15","author":"Lorenzoni","year":"2022","journal-title":"Health Serv Insights"},{"key":"2026021303311904200_bib38","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1185\/030079906X167327","article-title":"Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another","volume":"23","author":"Goeree","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2026021303311904200_bib39","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1093\/ndt\/gft214","article-title":"Cost of peritoneal dialysis and haemodialysis across the world","volume":"28","author":"Karopadi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026021303311904200_bib40","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/ndt\/gft528","article-title":"The role of economies of scale in the cost of dialysis across the world: a macroeconomic perspective","volume":"29","author":"Karopadi","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026021303311904200_bib41","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"2026021303311904200_bib42","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"2026021303311904200_bib43","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1681\/ASN.2019010008","article-title":"Evaluating glomerular filtration rate slope as a surrogate end point for ESKD in clinical trials: an individual participant meta-analysis of observational data","volume":"30","author":"Grams","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026021303311904200_bib44","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"key":"2026021303311904200_bib45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40273-020-00935-1","article-title":"Surrogate endpoints in health technology assessment: an international review of methodological guidelines","volume":"38","author":"Grigore","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"2026021303311904200_bib46","first-page":"65","article-title":"A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials","author":"Ciani","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2026021303311904200_bib47","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2215\/CJN.13821119","article-title":"End points for clinical trials in primary hyperoxaluria","volume":"15","author":"Milliner","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021303311904200_bib48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1053\/j.ajkd.2016.03.418","article-title":"The validity of left ventricular mass as a surrogate end point for all-cause and cardiovascular mortality outcomes in people with CKD: a systematic review and meta-analysis","volume":"68","author":"Badve","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2026021303311904200_bib49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/ndt\/gfq661","article-title":"The analysis of competing events like cause-specific mortality\u2014beware of the Kaplan-Meier method","volume":"26","author":"Verduijn","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2026021303311904200_bib50","doi-asserted-by":"publisher","first-page":"e219225","DOI":"10.1001\/jamanetworkopen.2021.9225","article-title":"Accounting for the competing risk of death to predict kidney failure in adults with stage 4 chronic kidney disease","volume":"4","author":"Al-Wahsh","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026021303311904200_bib51","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.kint.2018.01.009","article-title":"Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate","volume":"93","author":"Grams","year":"2018","journal-title":"Kidney Int"},{"key":"2026021303311904200_bib52","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jval.2024.12.009","article-title":"Rare disease policy in high-income countries: an overview of achievements, challenges, and solutions","volume":"28","author":"Gentilini","year":"2025","journal-title":"Value Health"},{"key":"2026021303311904200_bib53","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jval.2017.12.026","article-title":"Societal preferences for funding orphan drugs in the United Kingdom: an application of person trade-off and discrete choice experiment methods","volume":"21","author":"Bourke","year":"2018","journal-title":"Value Health"},{"key":"2026021303311904200_bib54","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.ajkd.2018.12.011","article-title":"Mortality in incident maintenance dialysis patients versus incident solid organ cancer patients: a population-based cohort","volume":"73","author":"Naylor","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026021303311904200_bib55","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jval.2024.02.013","article-title":"Understanding the National Institute for Health and Care Excellence severity premium: exploring its implementation and the implications for decision making and patient access","volume":"27","author":"Njoroge","year":"2024","journal-title":"Value Health"},{"key":"2026021303311904200_bib56","article-title":"Section 3.18 (severity weighting)","volume-title":"Difelikefalin for treating pruritus in people having haemodialysis","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"2026021303311904200_bib57","volume-title":"Assessing technologies that are not cost-effective at a zero price","author":"Davis","year":"2014"},{"key":"2026021303311904200_bib58","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.kint.2025.01.012","article-title":"Is online hemodiafiltration a cost-effective alternative to conventional hemodialysis?","volume":"107","author":"Erickson","year":"2025","journal-title":"Kidney Int"},{"key":"2026021303311904200_bib59","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/gfaa291","article-title":"Comorbidities and outcomes in South Asian individuals with chronic kidney disease: an observational primary care cohort","volume":"37","author":"Major","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026021303311904200_bib60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13293-021-00373-4","article-title":"Acute kidney injury is more common in men than women after accounting for socioeconomic status, ethnicity, alcohol intake and smoking history","volume":"12","author":"Loutradis","year":"2021","journal-title":"Biol Sex Differ"},{"key":"2026021303311904200_bib61","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/jpm11090845","article-title":"Mobile health, disease knowledge, and self-care behavior in chronic kidney disease: a prospective cohort study","volume":"11","author":"Tsai","year":"2021","journal-title":"J Pers Med"},{"key":"2026021303311904200_bib62","doi-asserted-by":"publisher","first-page":"sfad137","DOI":"10.1093\/ckj\/sfad137","article-title":"Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review","volume":"17","author":"Yeo","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026021303311904200_bib63","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jval.2022.06.011","article-title":"Distributional cost-effectiveness analysis of health technologies: data requirements and challenges","volume":"26","author":"Meunier","year":"2023","journal-title":"Value Health"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf386\/65817773\/sfaf386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/2\/sfaf386\/65817773\/sfaf386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/2\/sfaf386\/65817773\/sfaf386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:31:24Z","timestamp":1770971484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf386\/8374714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf386","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,9]]},"article-number":"sfaf386"}}